Zobrazeno 1 - 10
of 49
pro vyhledávání: '"Thomas Kuilman"'
Autor:
Sofía Ibáñez-Molero, Alex van Vliet, Joanna Pozniak, Karlijn Hummelink, Alexandra M. Terry, Kim Monkhorst, Joyce Sanders, Ingrid Hofland, Ewout Landeloos, Yannick Van Herck, Oliver Bechter, Thomas Kuilman, Weiwei Zhong, Jean-Christophe Marine, Lodewyk Wessels, Daniel S. Peeper
Publikováno v:
OncoImmunology, Vol 11, Iss 1 (2022)
Immunotherapies, in particular immune checkpoint blockade (ICB), have improved the clinical outcome of cancer patients, although many fail to mount a durable response. Several resistance mechanisms have been identified, but our understanding of the r
Externí odkaz:
https://doaj.org/article/cf4c583ffddb4dc1aa5667545d3848df
Autor:
Roelof J. C. Kluin, Kristel Kemper, Thomas Kuilman, Julian R. de Ruiter, Vivek Iyer, Josep V. Forment, Paulien Cornelissen-Steijger, Iris de Rink, Petra ter Brugge, Ji-Ying Song, Sjoerd Klarenbeek, Ultan McDermott, Jos Jonkers, Arno Velds, David J. Adams, Daniel S. Peeper, Oscar Krijgsman
Publikováno v:
BMC Bioinformatics, Vol 19, Iss 1, Pp 1-15 (2018)
Abstract Background Mouse xenografts from (patient-derived) tumors (PDX) or tumor cell lines are widely used as models to study various biological and preclinical aspects of cancer. However, analyses of their RNA and DNA profiles are challenging, bec
Externí odkaz:
https://doaj.org/article/6434550c4ed14fcc9809b0f01e508946
Autor:
Willemijn S M E Theelen, Thomas Kuilman, Katja Schulze, Wei Zou, Oscar Krijgsman, Dennis D G C Peters, Sten Cornelissen, Kim Monkhorst, Pranamee Sarma, Teiko Sumiyoshi, Lukas C Amler, Stefan M Willems, Johannes L G Blaauwgeers, Carel J M van Noesel, Daniel S Peeper, Michel M van den Heuvel, Marcin Kowanetz
Publikováno v:
PLoS ONE, Vol 14, Iss 5, p e0216864 (2019)
BackgroundIn non-small cell lung cancer (NSCLC), PD-L1 expression on either tumor cells (TC) or both TC and tumor-infiltrating immune cells (IC) is currently the most used biomarker in cancer immunotherapy. However, the mechanisms involved in PD-L1 r
Externí odkaz:
https://doaj.org/article/71ec07804c5045b0afac420650e42855
Autor:
Ekaterina A. Semenova, Min-chul Kwon, Kim Monkhorst, Ji-Ying Song, Rajith Bhaskaran, Oscar Krijgsman, Thomas Kuilman, Dennis Peters, Wieneke A. Buikhuisen, Egbert F. Smit, Colin Pritchard, Miranda Cozijnsen, Jan van der Vliet, John Zevenhoven, Jan-Paul Lambooij, Natalie Proost, Erwin van Montfort, Arno Velds, Ivo J. Huijbers, Anton Berns
Publikováno v:
Cell Reports, Vol 16, Iss 3, Pp 631-643 (2016)
Small cell lung cancer (SCLC) is an aggressive neuroendocrine tumor, and no effective treatment is available to date. Mouse models of SCLC based on the inactivation of Rb1 and Trp53 show frequent amplifications of the Nfib and Mycl genes. Here, we re
Externí odkaz:
https://doaj.org/article/0c5e4b5dae114c238369da8b5e06aff1
Autor:
Kristel Kemper, Oscar Krijgsman, Xiangjun Kong, Paulien Cornelissen-Steijger, Aida Shahrabi, Fleur Weeber, Daphne L. van der Velden, Onno B. Bleijerveld, Thomas Kuilman, Roel J.C. Kluin, Chong Sun, Emile E. Voest, Young Seok Ju, Ton N.M. Schumacher, A.F. Maarten Altelaar, Ultan McDermott, David J. Adams, Christian U. Blank, John B. Haanen, Daniel S. Peeper
Publikováno v:
Cell Reports, Vol 16, Iss 1, Pp 263-277 (2016)
The therapeutic landscape of melanoma is improving rapidly. Targeted inhibitors show promising results, but drug resistance often limits durable clinical responses. There is a need for in vivo systems that allow for mechanistic drug resistance studie
Externí odkaz:
https://doaj.org/article/b4e20b0f1b48444f832fabb5c11f6dd8
Autor:
Thomas Kuilman, Daniel S Peeper
Publikováno v:
EMBO Molecular Medicine, Vol 9, Iss 8, Pp 987-989 (2017)
Abstract Considerable clinical successes have been achieved in cancer treatment since the introduction of targeted therapies. However, almost inevitably tumors develop therapy resistance, which limits durable clinical responses. Tumors are often hete
Externí odkaz:
https://doaj.org/article/d4a423ed042e44a9b9383e214be15932
Autor:
Kristel Kemper, Oscar Krijgsman, Paulien Cornelissen‐Steijger, Aida Shahrabi, Fleur Weeber, Ji‐Ying Song, Thomas Kuilman, Daniel J Vis, Lodewyk F Wessels, Emile E Voest, Ton NM Schumacher, Christian U Blank, David J Adams, John B Haanen, Daniel S Peeper
Publikováno v:
EMBO Molecular Medicine, Vol 7, Iss 9, Pp 1104-1118 (2015)
Abstract The development of targeted inhibitors, like vemurafenib, has greatly improved the clinical outcome of BRAFV600E metastatic melanoma. However, resistance to such compounds represents a formidable problem. Using whole‐exome sequencing and f
Externí odkaz:
https://doaj.org/article/8743728c73b5476d9e877b496d1b360e
Publikováno v:
PLoS Genetics, Vol 11, Iss 1, p e1004907 (2015)
Substrate dephosphorylation by the cyclin-dependent kinase (Cdk)-opposing phosphatase, Cdc14, is vital for many events during budding yeast mitotic exit. Cdc14 is sequestered in the nucleolus through inhibitory binding to Net1, from which it is relea
Externí odkaz:
https://doaj.org/article/f27567ce0fb44b77a61ebc06262b23ab
Autor:
Sebastiaan M. Schieven, Joleen J.H. Traets, Alex v. Vliet, Martijn v. Baalen, Ji-Ying Song, Marcos Da Silva Guimaraes, Thomas Kuilman, Daniel S. Peeper
Publikováno v:
Molecular Cancer Research. 21:428-443
High expression of the receptor tyrosine kinase AXL is implicated in epithelial-to-mesenchymal transition, cancer progression, and therapy resistance. For example, AXL is abundant in BRAF mutant melanomas progressing on targeted BRAF/MEK inhibition.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d5fbd730ad2f83f9fe7b61b31ebe3f20
https://doi.org/10.1158/1541-7786.mcr-22-0648
https://doi.org/10.1158/1541-7786.mcr-22-0648
Autor:
Daniel S. Peeper, Thomas Kuilman, Marcos Da Silva Guimaraes, Ji-Ying Song, Martijn v. Baalen, Alex v. Vliet, Joleen J.H. Traets, Sebastiaan M. Schieven
Extended data on Figure 5: Low expression of ELOB/C is associated with phenotype switching and EMT.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1fe865d9dc43991afd75cff25b618ce5
https://doi.org/10.1158/1541-7786.22725420.v1
https://doi.org/10.1158/1541-7786.22725420.v1
